Trial Profile
Safety and Efficacy of Velcade in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2013
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Inc
- 03 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Sep 2009 Planned end date changed from 1 May 2012 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 30 Apr 2009 Investigational drug identified as 'Dexamethasone' as reported by ClinicalTrials.gov.